Askari Arman T, Shishehbor Mehdi H, Kaminski Matthew A, Riley Michael J, Hsu Amy, Lincoff A Michael
Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
Am Heart J. 2009 Aug;158(2):238-43. doi: 10.1016/j.ahj.2009.05.023.
The long-term prognostic significance of early (<48 hours) ventricular fibrillation (VF) or sustained ventricular tachycardia (VT) in patients with an acute myocardial infarction remains controversial. Emerging data suggest that some of the benefit of renin-angiotensin-aldosterone system (RAAS) antagonism may be derived from a reduction in the incidence of these arrhythmias in the setting of acute myocardial infarction.
We assessed the relationship between early VF/VT (defined as within 48 hours after admission) and mortality in 16,588 patients from global use of strategies to open coronary arteries (GUSTO) V trial. Furthermore, we examined the relationship between baseline use of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), early VF/VT, and mortality.
Early VF or VT occurred in 732 (4.4%) patients. Compared to patients without VF/VT, those experiencing early VF or VT had a significant increase in 30-day mortality (22% vs 5%, P < .001). Baseline use of an ACEI/ARB was associated with a decreased incidence of early VF/VT (odds ratio 0.65, 0.47-0.89, P = .008). A lower 30-day mortality was seen in patients with early VF/VT on baseline ACEI/ARB compared with patients with early VF/VT not receiving an ACEI/ARB at baseline (17.7% vs 24.2%, respectively, P = .04). The association between baseline RAAS antagonism and mortality persisted after adjustment for multiple confounders.
In patients presenting with acute myocardial infarction, early VF/VT identifies those at increased risk for 30-day mortality. Baseline use of RAAS antagonists is associated with a reduced incidence of malignant arrhythmias. Identifying how this association impacts short-term mortality in this patient population requires further prospective evaluation.
急性心肌梗死患者早期(<48小时)室颤(VF)或持续性室性心动过速(VT)的长期预后意义仍存在争议。新出现的数据表明,肾素-血管紧张素-醛固酮系统(RAAS)拮抗作用的部分益处可能源于急性心肌梗死时这些心律失常发生率的降低。
我们评估了全球应用冠状动脉开通策略(GUSTO)V试验中16588例患者早期VF/VT(定义为入院后48小时内)与死亡率之间的关系。此外,我们还研究了血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体阻滞剂(ARB)的基线使用情况、早期VF/VT与死亡率之间的关系。
732例(4.4%)患者发生早期VF或VT。与未发生VF/VT的患者相比,发生早期VF或VT的患者30天死亡率显著增加(22%对5%,P<.001)。ACEI/ARB的基线使用与早期VF/VT发生率降低相关(比值比0.65,0.47 - 0.89,P =.008)。与基线时未接受ACEI/ARB的早期VF/VT患者相比,基线时使用ACEI/ARB的早期VF/VT患者30天死亡率较低(分别为17.7%对24.2%,P =.04)。在对多个混杂因素进行调整后,基线RAAS拮抗与死亡率之间的关联仍然存在。
在急性心肌梗死患者中,早期VF/VT可识别出30天死亡率增加的患者。RAAS拮抗剂的基线使用与恶性心律失常发生率降低相关。确定这种关联如何影响该患者群体的短期死亡率需要进一步的前瞻性评估。